Herantis Pharma Announces 12-Month Follow-Up Review from Phase 1 Lymfactin Trial in Breast Cancer-Associated Lymphedema
Herantis Pharma Announces 12-Month Follow-Up Review from Phase 1 Lymfactin® Trial in Breast Cancer-Associated Lymphedema Herantis Pharma PlcCompany release 23 April 2019 at 9:00 am Herantis Pharma Plc (“Herantis”) announced today the topline results from the 12-month follow-up review of the Phase 1 Lymfactin® trial in breast cancer-associated lymphedema. The study’s data monitoring committee (DMC) concluded that the treatment continues to be safe and well-tolerated in all patients with no severe adverse events. Lymfactin®, the novel gene therapy of Herantis that aims to repair the